Suppr超能文献

重复碳离子放疗治疗肝内复发性肝细胞癌。

Repeated Carbon-Ion Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma.

机构信息

Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan.

Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan; Gunma University Heavy Ion Medical Center, Maebashi, Japan.

出版信息

Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):1100-1109. doi: 10.1016/j.ijrobp.2023.02.036. Epub 2023 Mar 3.

Abstract

PURPOSE

This retrospective study aimed to evaluate the safety and efficacy of repeated carbon-ion radiation therapy (CIRT) in patients with intrahepatic recurrent hepatocellular carcinoma (HCC).

METHODS AND MATERIALS

We reviewed patients who underwent repeated CIRT for intrahepatic recurrent HCC between 2010 and 2020.

RESULTS

Forty-one patients received multiple CIRT courses for HCC. During the second course, 17 (41.5%) and 24 (58.5%) of 41 patients underwent CIRT for local recurrence (LR) and intrahepatic recurrence after the first irradiation, respectively. The median age at the first course was 76 years, and the median tumor size in all the courses was 25 mm. Throughout all CIRT courses, the prescribed dose was 52.8 to 60.0 Gy (relative biological effectiveness), which was delivered in 4 to 12 fractions. The median follow-up period after the first and second CIRT was 40 and 21 months. Median overall survival (OS) after the first and second CIRT were 80 and 27 months, respectively. The 2- and 5-year OS after the first CIRT were 87.8% and 50.1%, and the 2-year OS rate after the second CIRT was 56.0%. The 1- and 2-year local control (LC) after the second CIRT was 93.4% and 83.0%, respectively. The median progression-free survival (PFS) after the second CIRT was 11 months. There were no significant differences in the LC and PFS between patients with LR and out-of-field recurrence (P = .83; 0.28, respectively). The albumin-bilirubin scores at 3 and 6 months after the second CIRT were not significantly different from those before irradiation. According to the Common Terminology Criteria for Adverse Events version 4.0, grade 4 or greater toxicities were not observed.

CONCLUSIONS

Repeated CIRT for intrahepatic recurrent HCC was safe and effective, including reirradiation for LR. OS, LC, and PFS were satisfactory, and liver function was preserved. Repeated CIRT could be considered a treatment option for intrahepatic recurrent HCC.

摘要

目的

本回顾性研究旨在评估碳离子放射治疗(CIRT)在肝内复发性肝细胞癌(HCC)患者中的安全性和疗效。

方法与材料

我们回顾了 2010 年至 2020 年间接受肝内复发性 HCC 多次 CIRT 治疗的患者。

结果

41 例患者接受多次 HCC CIRT 治疗。在第二疗程中,41 例患者中有 17 例(41.5%)和 24 例(58.5%)分别因第一次照射后的局部复发(LR)和肝内复发而接受 CIRT。第一次疗程的中位年龄为 76 岁,所有疗程的中位肿瘤大小为 25mm。在所有 CIRT 疗程中,处方剂量为 52.8 至 60.0Gy(相对生物效应),分 4 至 12 次给予。第一次和第二次 CIRT 后的中位随访时间分别为 40 个月和 21 个月。第一次和第二次 CIRT 后的中位总生存期(OS)分别为 80 个月和 27 个月。第一次 CIRT 后 2 年和 5 年的 OS 分别为 87.8%和 50.1%,第二次 CIRT 后 2 年的 OS 率为 56.0%。第二次 CIRT 后 1 年和 2 年的局部控制率(LC)分别为 93.4%和 83.0%。第二次 CIRT 后无进展生存期(PFS)的中位值为 11 个月。LR 和野外复发患者的 LC 和 PFS 无显著差异(P=0.83;0.28)。第二次 CIRT 后 3 个月和 6 个月的白蛋白-胆红素评分与照射前无显著差异。根据不良事件通用术语标准 4.0 版,未观察到 4 级或更高级别的毒性。

结论

肝内复发性 HCC 的重复 CIRT 是安全有效的,包括对 LR 的再照射。OS、LC 和 PFS 令人满意,肝功能得以保留。重复 CIRT 可被视为肝内复发性 HCC 的一种治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验